|

PF-08046050 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: SAR445953; SGN-CEACAM5C

Pipeline

Phase 1: 1

Top Sponsors

  • Seagen, a wholly owned subsidiary of Pfizer1

Indications

  • Gastroesophageal Junction Adenocarcinoma1
  • Small Cell Lung Carcinoma1
  • Pancreatic Ductal Adenocarcinoma1
  • Stomach Neoplasms1
  • Carcinoma, Non-Small-Cell Lung1

Phoenix, Arizona1 trial

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Mayo Clinic Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.